FDA actions, clinical trial results, and peer-reviewed findings, most recent first.
Legal industry coverage of the FDA's April 2026 Federal Register notice confirms the Pharmacy Compounding Advisory Committee (PCAC) — the body that voted in July 2026 to recommend six peptides for the 503A Bulks List — will reconvene by the end of February 2027 to review five additional peptides for compounding eligibility: GHK-Cu, Melanotan II, Cathelicidin (LL-37), Dihexa acetate, and PEG-MGF (pegylated Mechano Growth Factor). As with the July review, FDA staff will present a scientific evaluation of each substance before the committee votes on a recommendation, and becoming eligible for compounding would not constitute FDA approval or a determination that a peptide is safe or effective for its promoted uses.
Related peptides: GHK-Cu →Melanotan II →LL-37 →Dihexa →PEG-MGF →
In an August 3 episode of its Public Health On Call podcast, the Johns Hopkins Bloomberg School of Public Health published an expert interview with Dr. Joshua Sharfstein, a former FDA Principal Deputy Commissioner, breaking down the outcome of the FDA's Pharmacy Compounding Advisory Committee meeting: the panel voted to recommend that six of the seven peptides under review be permitted for compounding, over the objection of the agency's own scientific staff, who cited insufficient safety and efficacy evidence. Sharfstein noted the panel's makeup had been criticized for financial conflicts of interest, and that the decision now returns to the FDA, which must determine whether and how to formally add the compounds to its permitted-compounding list — a process that could stretch into 2028 unless HHS invokes special authority to move faster.
Related peptides: BPC-157 →TB-500 →Thymosin Alpha-1 →CJC-1295 →Ipamorelin →AOD-9604 →GHK-Cu →Selank →Semax →KPV →MOTS-c →
Louisiana Senate Bill 253, introduced by Sen. McMath in the 2026 Regular Session, would enact a new state law prohibiting professional and occupational licensing boards from stopping a prescribing healthcare provider from supplying patients with peptides sourced from an FDA-registered 503B outsourcing facility or a 503A compounding pharmacy that buys its active ingredients from an FDA-registered manufacturer — with the requirement that any peptide prescribed under the law not appear on the FDA's prohibited compounding list.
Related peptides: BPC-157 →TB-500 →Thymosin Alpha-1 →CJC-1295 →Ipamorelin →
The FDA's Pharmacy Compounding Advisory Committee voted across July 23–24, 2026 on whether seven research peptides should be added to the list governing what compounding pharmacies may legally prepare. Six of seven — including BPC-157, TB-500, MOTS-c, Epithalon, and Semax — received recommending votes, overriding the agency's own staff review, which had argued the safety and effectiveness data was insufficient. The vote is non-binding; a final FDA rulemaking decision is still pending.
Related peptides: BPC-157 →TB-500 →MOTS-c →Epithalon →Semax →
Eli Lilly announced topline results from two additional pivotal Phase 3 trials of retatrutide, its investigational triple GIP/GLP-1/glucagon receptor agonist, meeting primary weight-loss and cardiometabolic endpoints in adults with obesity, type 2 diabetes, and established cardiovascular disease. Combined with earlier TRIUMPH-1 data showing 28.3% average weight loss at 80 weeks, the company said it plans to submit a Biologics License Application to the FDA in the first quarter of 2027, with a potential approval window in late 2027 to 2028.
Related peptides: Retatrutide →
The FDA published a proposed determination that semaglutide, tirzepatide, and liraglutide no longer meet the statutory criteria for large-scale 503B outsourcing-facility compounding, concluding there is no clinical need given that both drug shortages were declared resolved in late 2024 and early 2025. The move would close the legal pathway for industrial-scale compounded versions of these GLP-1 medications; patient-specific 503A compounding with documented medical necessity remains a separate, lawful pathway.
Related peptides: Semaglutide →Tirzepatide →
A science-journalism examination of the peptide wellness boom finds that most popularly used compounds — including BPC-157, GHK-Cu, and ipamorelin — have limited clinical evidence despite widespread promotion by influencers and biohacking communities. The article notes that in 2023 the FDA barred US compounding pharmacies from producing several of these peptides, including BPC-157, GHK-Cu, and ipamorelin, citing significant safety risks, pushing many users toward unregulated overseas suppliers.
Related peptides: BPC-157 →GHK-Cu →Ipamorelin →
The FDA updated its Bulk Drug Substances Nominated for Use in Compounding list, providing notice that it would remove twelve peptide bulk drug substances — including BPC-157, TB-500, MOTS-c, Semax, Epitalon, and GHK-Cu (injectable) — from Category 2 after their nominators withdrew the underlying safety-risk nominations. The agency simultaneously published a Federal Register notice scheduling Pharmacy Compounding Advisory Committee meetings for July 23–24, 2026 and before the end of February 2027 to formally evaluate whether these substances should be added to the 503A bulks list. FDA emphasized that removal from Category 2 does not by itself authorize compounding.
Related peptides: BPC-157 →TB-500 →MOTS-c →Semax →Epithalon →GHK-Cu →CJC-1295 →
A peer-reviewed review published in the International Journal of Molecular Sciences synthesizes preclinical evidence that BPC-157 supports angiogenesis, collagen synthesis, fibroblast activity, and nitric oxide pathway modulation, contributing to healing across muscle, tendon, ligament, bone, and gastrointestinal tissue. The authors report reduced inflammatory cytokine activity and pain-modulating effects via peripheral and dopaminergic mechanisms, while noting human clinical evidence remains limited to small pilot studies.
Related peptides: BPC-157 →
A co-published investigation by STAT and Undark examines the scientific literature behind BPC-157's popularity, finding that nearly all existing data originates from a single Croatian research group's rodent studies. A University of Utah chief medical resident's formal literature review found the animal evidence for angiogenesis, anti-inflammatory, and tendon-healing effects credible in rodents, but identified no adequately powered human trials supporting the therapeutic claims driving the compound's popularity.
Related peptides: BPC-157 →
Researchers retrospectively reviewed medical records from a commercial wellness clinic to compare tolerability and short-term safety between intravenous NAD+ and nicotinamide riboside (NR) infusions, each given as four consecutive daily doses with 30-day follow-up. The study found differences in infusion time and tolerability between the two, while exploratory metabolic outcomes were variable — the authors noted that both are increasingly offered in commercial and wellness settings despite limited published evaluation of their safety and effectiveness.
Related peptides: NAD+ →
Researchers analyzed 21 years of adverse event reports submitted to the FDA's Adverse Event Reporting System (FAERS) for pentosan polysulfate sodium, characterizing its post-marketing safety profile including reports of pigmentary maculopathy associated with long-term use — the retinal safety signal that has prompted updated monitoring guidance for patients on extended therapy.
Related peptides: Pentosan Polysulfate →
An investigation into the gray-market peptide trend spreading through Silicon Valley's tech and startup scene, where compounds including BPC-157, TB-500, and thymosin alpha-1 are sourced directly from Chinese manufacturers outside FDA oversight. The piece traces the trend from private parties and 'hacker houses' to organized 'peptide raves,' and examines the regulatory gray zone these products occupy as imports of hormone and peptide compounds from China roughly doubled year over year.
Related peptides: BPC-157 →TB-500 →Thymosin Alpha-1 →
The Centers for Medicare & Medicaid Services announced the BALANCE Model, a voluntary alternative payment model under which CMS will negotiate directly with GLP-1 manufacturers for lower net prices, capped out-of-pocket costs, and standardized coverage criteria for Medicare Part D and state Medicaid programs. A companion 'Medicare GLP-1 Bridge' demonstration launches July 1, 2026, offering eligible beneficiaries access at a $50 monthly copay ahead of BALANCE's full Medicaid rollout (as early as May 2026) and Part D rollout (January 2027).
Related peptides: Semaglutide →Tirzepatide →
The FDA approved Forzinity (elamipretide HCl) to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg — the first approved therapy for this ultra-rare mitochondrial disease and the first FDA-approved mitochondria-targeted therapeutic of any kind. Approval was based on improvement in knee extensor muscle strength as an intermediate clinical endpoint under the accelerated approval pathway.
Related peptides: SS-31 →
The SURMOUNT-5 head-to-head trial found tirzepatide produced significantly greater mean weight reduction than semaglutide at 72 weeks (20.2% vs. 13.7%) in adults with obesity, establishing the first direct randomized comparison between the two leading GLP-1-class therapies for chronic weight management.
Related peptides: Tirzepatide →Semaglutide →
In a 22-center, 1,106-patient phase 3 randomized controlled trial conducted in China, thymosin alpha-1 did not significantly reduce 28-day all-cause mortality in adults with sepsis compared with placebo (23.4% vs. 24.1%; hazard ratio 0.99). No secondary or safety outcome differed significantly between groups — a rigorously controlled result that tempers earlier, smaller studies suggesting benefit.
Related peptides: Thymosin Alpha-1 →
The FDA announced that AOD-9604, CJC-1295, Ipamorelin acetate, Thymosin Alpha-1, and Selank acetate were being removed from Category 2 of the agency's interim 503A bulk drug substances policy after their original safety-risk nominations were withdrawn, referring each to the Pharmacy Compounding Advisory Committee for formal review — the first procedural step toward potential compounding eligibility.
Related peptides: CJC-1295 →Ipamorelin →Thymosin Alpha-1 →Selank →
In a randomized clinical trial of 32 men with hypoactive sexual desire disorder, kisspeptin administration significantly modulated brain activity in key regions of the sexual-processing network compared with placebo, and increased behavioral measures of sexual desire and penile tumescence in response to visual sexual stimuli — early evidence supporting kisspeptin-based therapeutics for low sexual desire in men.
Related peptides: Kisspeptin-10 →